At long last the new year is upon us, and I am more excited about the trade of the decade than ever before. Now that we have a clearer picture of all the new regulations and how they will impact the small regional and community bank I think we will see merger activity pick up in the sector.
Top Forestry Stocks To Watch Right Now: NetSol Technologies Inc.(NTWK)
Netsol Technologies, Inc. designs, develops, and markets software products for the automobile finance and leasing, banking, healthcare, and financial services industries worldwide. It offers NetSol Financial Suite, which is an end-to-end solution that covers the leasing and finance cycle. The NetSol Financial Suite consist of software applications comprising Point of Sale, a front office processing system for the finance sector; Credit Application Processing System to handle the incoming credit applications from dealers, agents, brokers, and the direct sales force; Contract Management System to manage and maintain a contract; Wholesale Finance System to automate and manage the floor plan/bailment activities of dealerships; and Fleet Management System to handle fleet management needs. The NetSol Financial Suite also includes LeasePak that develops Web-enabled and Web-based tools for the leasing technology industry. In addition, the company offers LeaseSoft Portals and Modul es; enterprise wide information systems, such as LRMIS, MTMIS, and Hospital Management Systems; accounting outsourcing services; and career and technology programs. Further, it provides portfolio management systems for the financial services industry; and consulting, custom development, systems integration, and technical services for the healthcare, insurance, real estate, and technology markets. Additionally, the company offers business intelligence, independent system review, information security, and software process improvement consulting services; maintenance and support, and project management services; and solutions for the defense and military forces. It serves Fortune 500 manufacturers, automakers, financial institutions, utilities, technology providers, and government agencies. The company was formerly known as NetSol International, Inc. and changed its name to NetSol Technologies, Inc. in March 2002. NetSol Technologies, Inc. was founded in 1997 and is based in Ca labasas, California.
Advisors' Opinion:- [By CRWE]
NetSol Technologies (Nasdaq:NTWK), a provider of global IT and enterprise application solutions, reported that Mercedes-Benz Leasing Company Ltd. (China), went live with the NetSol Financial Suite (NFS(tm)).
- [By Roberto Pedone]
Another under-$10 stock that's quickly pushing within range of triggering a near-term breakout trade is Netsol Technologies (NTWK), which designs, develops, markets and exports proprietary software products to customers in the automobile finance and leasing, banking, health care and financial services industries internationally. This stock is off to a strong start in 2013, with shares up by 28%.
If you take a look at the chart for Netsol Technologies, you'll notice that this stock has been downtrending badly for the last two months, with shares sliding sharply lower from its high of $12.10 to its recent low of $7.03 a share. During that downtrend, shares of NTWK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of NTWK have started to stabilize and reverse its downtrend, since the stock has started to make higher lows and higher highs over the last few weeks. This move is quickly pushing shares of NTWK within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in NTWK if it manages to break out above some near-term overhead resistance at $7.74 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 225,909 shares. If that breakout hits soon, then NTWK will set up to re-test or possibly take out its next major overhead resistance levels at $8.71 to its 50-day moving average at $9.16 a share. Any high-volume move above those levels will then give NTWK a chance to tag its 200-day at $10.20 to more resistance at $10.45 a share.
Traders can look to buy NTWK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $7.20 or $7.03 a share. One can also buy NTWK off strength once it clears $7.74 a share with volume and then simply use a stop that sits a comfortable percentage fr
Best Regional Bank Stocks To Invest In 2014: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
Best Regional Bank Stocks To Invest In 2014: Tim Participacoes SA (TIMP3)
TIM Participacoes SA (TIM) is a Brazil-based holding company engaged in the telecommunications segment. Through its wholly-owned subsidiaries, TIM Celular SA (TIM Celular) and Intelig Telecomunicacoes Ltda (Intelig), it provides telecommunication services throughout Brazil. TIM Celular and Intelig are active as Public Switched Telephony Network (PSTN) providers in the local and national and international long-distance modalities in all Brazilian states. Additionally, the Company provides multimedia communication services and personal mobile services, mobile data services and a third generation (3G) network, as well as international roaming agreements, multimedia messaging services, blackberry services and sale of related equipment. Advisors' Opinion:- [By Jonathan Morgan]
Telecom Italia SpA (TIT) jumped 6.2 percent to 65.6 euro cents. The phone company that was stripped of its investment-grade rating is seeking at least 9 billion euros for its controlling stake in Brazilian wireless carrier Tim Participacoes SA (TIMP3), according to a person with direct knowledge of the matter.
Best Regional Bank Stocks To Invest In 2014: PartnerRe Ltd (PRE)
PartnerRe Ltd. (PartnerRe), incorporated in August 24, 1993, is the ultimate holding company for its international reinsurance group. The Company provides reinsurance on a global basis through its wholly owned subsidiaries, including Partner Reinsurance Company Ltd. (PartnerRe Bermuda), Partner Reinsurance Europe plc (PartnerRe Europe) and Partner Reinsurance Company of the U.S. (PartnerRe U.S.). Its risks reinsured include property, casualty, motor, agriculture, aviation/space, catastrophe, credit/surety, engineering, energy, marine, specialty property, specialty casualty, multiline and other lines and mortality, longevity and health. The Company also offers alternative risk products, which include weather and credit protection to financial, industrial and service companies on a global basis. In January 2013, the Company acquired Presidio Reinsurance Group, a United States-based specialty accident and health reinsurance and insurance writer. In March 2013, the Company announced the formation of Lorenz Re Ltd.
The Company provides reinsurance for its clients in approximately 150 countries globally. Through its branches and subsidiaries, the Company provides reinsurance of non-life and life risks to ceding companies (primary insurers, cedants or reinsureds) on either a proportional or non-proportional basis through treaties or facultative reinsurance. The Company operates in three segments: Non-life, Life and Corporate and Other. Its Corporate and Other segment is consisted of the capital markets and investment related activities of the Company, including principal finance transactions, insurance-linked securities and strategic investments, and its corporate activities, including other operating expenses.
Non-life Segment
The Non-life segment is divided into four sub-segments, North America, Global (Non-the United States) Property and Casualty (Global (Non-the United States) P&C), Global (Non-the United States) Specialty and Catastrophe. The North America sub-seg! ment includes agriculture, casualty, motor, multiline, property, surety and other risks generally originating in the United States. The Global (Non-the United States) P&C sub-segment includes casualty, motor and property business generally originating outside of the United States. The Global (Non-the United States) Specialty sub-segment business include agriculture, aviation/space, credit/surety, energy, engineering, marine, specialty casualty, specialty property and other lines. The Catastrophe sub-segment is consisted of the Company�� catastrophe line of business. The Company reinsures, primarily on a proportional basis, agricultural yield and price/revenue risks related to flood, drought, hail and disease related to crops, livestock and aquaculture. The Company provides specialized reinsurance protection for airline, general aviation and space insurance business on a proportional basis and through facultative arrangements.
The Company�� space business relates to coverages for satellite assembly, launch and operation for commercial space programs. Its casualty business includes third party liability, employers��liability, workers��compensation and personal accident coverages written on both a proportional and non-proportional basis, including structured reinsurance of casualty risks. The Company provides property catastrophe reinsurance protection, written on a non-proportional basis, against the accumulation of losses caused by windstorm, earthquake, tornado, tropical cyclone, flood or by any other natural hazard, which is covered under a property policy. Credit reinsurance, written on a proportional basis, provides coverage to commercial credit insurers, and the surety line relates to bonds and other forms of security written by specialized surety insurers. The Company provides reinsurance coverage for the onshore oil and gas industry, mining, power generation and pharmaceutical operations on a proportional basis and through facultative arrangements.
The Company p! rovides r! einsurance for engineering projects globally, predominantly on a proportional treaty basis and through facultative arrangements. The Company provides reinsurance protection and technical services relating to marine hull, cargo, transit and offshore oil and gas operations on a proportional or non-proportional basis. The Company�� motor business includes reinsurance coverages for third party liability and property damage risks arising from both passenger and commercial fleet automobile coverages written by cedants. This business is written predominantly on a proportional basis.
The Company�� multiline business provides both property and casualty reinsurance coverages written on both a proportional and non-proportional basis. Property business provides reinsurance coverage to insurers for property damage or business interruption losses resulting from fires, catastrophes and other perils covered in industrial, commercial property and homeowners��policies, and are written on both a proportional and non-proportional basis. The Company�� predominant exposure under these property coverage is to property damage. The Company�� property reinsurance treaties exclude certain risks, such as war, nuclear, biological and chemical contamination, radiation and environmental pollution.
The Company provides specialized reinsurance protection for non-the United States casualty business. This reinsurance protection is offered on a proportional, non-proportional or facultative basis. The Company provides specialized reinsurance protection for non-the United States property business. This reinsurance protection is offered on a proportional, non-proportional or facultative basis. The Company�� Non-life business is produced both through brokers and through direct relationships with insurance companies. In North America, business is written through brokers, while globally, the business is written on both a direct and broker basis.
Life Segment
The Company�� Life ! segment i! ncludes the mortality, longevity and health lines of business written primarily in the United Kingdom, Ireland and France. The Company provides reinsurance coverage to life insurers and pension funds to against individual and group mortality and disability risks. Mortality business is written on a proportional basis through treaty agreements. Mortality business is subdivided into death and disability covers (with various riders) written in Continental Europe, term assurance and critical illness (TCI) written in the United Kingdom and Ireland, and guaranteed minimum death benefit (GMDB) written in Continental Europe. The Company also writes certain treaties on a non-proportional basis in France.
The Company provides reinsurance coverage to employer sponsored pension schemes and life insurers who issue annuity contracts offering long-term retirement benefits to consumers, who seek protection against outliving their financial resources. The Company�� longevity portfolio is subdivided into standard and non-standard annuities. The non-standard annuities are annuities sold to consumers with aggravated health conditions and are underwritten on an individual basis. The Company provides reinsurance coverage to life insurers with respect to individual and group health risks. The Company�� Life business is produced both through brokers and through direct relationships with insurance companies. During the year ended December 31, 2011, one cedant accounted for 13% of the Life segment�� total gross premiums written and one broker, the Aon Group (including the Benfield Group), accounted for 16% of the Life segment�� total gross premiums written.
The Company competes with Munich Re, Swiss Re, Everest Re, Hannover Re, SCOR, Transatlantic, Arch Capital, Axis Capital and XL Group.
Advisors' Opinion:- [By Marc Bastow]
International insurance holding company PartnerRe Ltd. (PRE) raised its quarterly dividend 5% to 67 cents per share, payable on Feb. 28 to shareholders of record as of Feb. 18.
PRE Dividend Yield: 2.72%
No comments:
Post a Comment